Sixty one percent of the kidney transplant recipients were male, and most of them had arterial hypertension (91%) and received non-mTOR-inhibitor based regimen (64%) (mainly tacrolimus-mycophenolic acid) and 36% an mTOR-inhibitor based regimen (sirolimus or everolimus). Here, MTOR is linked to Hypertension.